Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/14/2025

Treatment of Latent Tuberculosis Infection

Preferred Regimens

  • The Centers for Disease Control and Prevention recommends 3 months of once-weekly isoniazid plus rifapentine, 4 months of daily rifampin, or 3 months of daily isoniazid plus rifampin for latent tuberculosis infection treatment, with excellent efficacy and higher completion rates than longer regimens 1
  • The American Thoracic Society strongly recommends 3 months of once-weekly isoniazid plus rifapentine with moderate quality evidence, as effective as 9 months of isoniazid alone in preventing tuberculosis with higher treatment completion rates 1
  • The Infectious Diseases Society of America strongly recommends 4 months of daily rifampin with moderate quality evidence for HIV-negative individuals, demonstrating non-inferiority to 9 months of isoniazid with better safety profiles and higher completion rates 1

Alternative Regimens

  • The Centers for Disease Control and Prevention strongly recommends 6 months of daily isoniazid for HIV-negative adults and children and conditionally recommends it for HIV-positive individuals 1, 2
  • The American Thoracic Society conditionally recommends 9 months of daily isoniazid for all adults and children, both HIV-negative and HIV-positive 1, 2

Special Considerations

  • The Centers for Disease Control and Prevention recommends 9 months of isoniazid rather than 6 months for persons with HIV infection when isoniazid is chosen for treatment of LTBI 3, 4
  • The Infectious Diseases Society of America recommends isoniazid plus antiretroviral therapy to decrease the incidence of TB disease to a greater extent than either isoniazid alone or antiretroviral therapy alone 5
  • The American Thoracic Society recommends rifabutin as a substitute for rifampin when rifampin cannot be used due to drug interactions with antiretroviral medications 3

Monitoring and Safety Considerations

  • The Centers for Disease Control and Prevention recommends ruling out active TB by history, physical examination, chest radiography, and bacteriologic studies when indicated before beginning treatment of LTBI 2, 3
  • The American Thoracic Society recommends follow-up evaluations at least monthly for isoniazid or rifampin monotherapy, and at 2, 4, and 8 weeks for rifampin plus pyrazinamide regimens 3
  • The Infectious Diseases Society of America recommends baseline laboratory testing for patients with risk factors for hepatotoxicity 6
  • The Centers for Disease Control and Prevention notes that hepatotoxicity risk is higher with rifampin and pyrazinamide given together than with either drug alone 5

Potential Pitfalls and Caveats

  • The American Thoracic Society warns of common drug interactions with rifamycins, particularly with warfarin, oral contraceptives, antifungals, and HIV antiretroviral therapy 5
  • The Infectious Diseases Society of America recommends monitoring patients on rifamycin-based regimens for symptoms of liver injury, especially those with abnormal baseline liver tests or liver disease 5